Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins

  • Jiménez, Maddalen
  • Urtasun Alonso, Raquel
  • Elizalde, María
  • Azkona, María
  • Latasa, Maria Ujue
  • Uriarte, Iker
  • Arechederra, María
  • Alignani, Diego
  • Bárcena-Varela, Marina
  • Álvarez-Sola, Gloria
  • Colyn, Leticia
  • Santamaría, Eva
  • Sangro, Bruno
  • Rodriguez-Ortigosa, Carlos
  • Fernández-Barrena, Maite G.
  • Ávila, Matías A.
  • Berasain, Carmen
Genome instability is related to disease development and carcinogenesis. DNA lesions are caused by genotoxic compounds but also by the dysregulation of fundamental processes like transcription, DNA replication and mitosis. Recent evidence indicates that impaired expression of RNA-binding proteins results in mitotic aberrations and the formation of transcription-associated RNA-DNA hybrids (R-loops), events strongly associated with DNA injury. We identify the splicing regulator SLU7 as a key mediator of genome stability. SLU7 knockdown results in R-loops formation, DNA damage, cell-cycle arrest and severe mitotic derangements with loss of sister chromatid cohesion (SCC). We define a molecular pathway through which SLU7 keeps in check the generation of truncated forms of the splicing factor SRSF3 (SRp20) (SRSF3-TR). Behaving as dominant negative, or by gain-of-function, SRSF3-TR impair the correct splicing and expression of the splicing regulator SRSF1 (ASF/SF2) and the crucial SCC protein sororin. This unique function of SLU7 was found in cancer cells of different tissue origin and also in the normal mouse liver, demonstrating a conserved and fundamental role of SLU7 in the preservation of genome integrity. Therefore, the dowregulation of SLU7 and the alterations of this pathway that we observe in the cirrhotic liver could be involved in the process of hepatocarcinogenesis., CIBERehd; Instituto de Salud Carlos III (ISCIII) [PI13/00359, PI13/00385]; MINECO/AEI/FEDER,UE [SAF2016-75972-R]; HEPACARE Project from Fundación La Caixa; Ministerio de Educación FPI Fellowship, Cultura y Deporte; ADA-UNAV and CIMA Fellowships; AECC Post-doctoral Fellowship; Fundación Eugenio Rodríguez Pascual; Fundación Echebano; Fundación Mario Losantos; Fundación M Torres and Mrs Eduardo Ávila and Sergio Durá contribution. Funding for open access charge: MINECO/AEI/FEDER,UE [SAF2016-75972-R].
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Bile acids, FGF15/19 and liver regeneration: from mechanisms to clinical applications

  • Álvarez-Sola, Gloria
  • Uriarte, Iker
  • Latasa, Maria Ujue
  • Jiménez, Maddalen
  • Bárcena-Varela, Marina
  • Santamaría, Eva
  • Urtasun Alonso, Raquel
  • Rodriguez-Ortigosa, Carlos
  • Prieto, Jesús
  • Berraondo, Pedro
  • Fernández-Barrena, Maite G.
  • Berasain, Carmen
  • Ávila, Matías A.
The liver has an extraordinary regenerative capacity rapidly triggered upon injury or resection. This response is intrinsically adjusted in its initiation and termination, a property termed the “hepatostat”. Several molecules have been involved in liver regeneration, and among them bile acids may play a central role. Intrahepatic levels of bile acids rapidly increase after resection. Through the activation of farnesoid X receptor (FXR), bile acids regulate their hepatic metabolism and also promote hepatocellular proliferation. FXR is also expressed in enterocytes, where bile acids stimulate the expression of fibroblast growth factor 15/19 (FGF15/19), which is released to the portal blood. Through the activation of FGFR4 on hepatocytes FGF15/19 regulates bile acids synthesis and finely tunes liver regeneration as part of the “hepatostat”. Here we review the experimental evidences supporting the relevance of the FXR-FGF15/19-FGFR4 axis in liver regeneration and discuss potential therapeutic applications of FGF15/19 in the prevention of liver failure., Work in the authors' laboratory is supported by CIBERehd and Grants from Instituto de Salud Carlos III (ISCIII) co-financed by “Fondo Europeo de Desarrollo Regional” (FEDER) “Una manera de hacer Europa”, numbers: FIS PI13/00359, PI13/00385 and PI16/01126.